Pfizer/Lilly ready to ditch painful past with new tanezumab trials

After five years of waiting, Pfizer and Lilly are ready to restart late-stage clinical trials for the pain drug tanezumab, the big pharmas announced 23 March. The move forward scores Pfizer a $200m milestone payment and signals a jumpstart for the class of drugs.